SCI时时刷

search
+
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared wit...
The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9
Immunotherapy has demonstrated promise as a treatment for acute myeloid leukemia (AML). However, there is still an urgent ...
Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 ...
A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones
A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones
Clonal hematopoiesis (CH) is nearly universal in the elderly. The molecular and cellular mechanisms driving CH and the cli...
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study
Competing interests DT received research funding from Sobi, Sumitomo, Cogent Bio...
Genomic profiling of circulating tumor DNA for childhood cancers
Genomic profiling of circulating tumor DNA for childhood cancers
The utility of circulating tumor DNA (ctDNA) analysis has not been well-established for disease detection and monitoring o...
Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia
Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia
The central role of the endothelial microenvironment in orchestrating bone marrow (BM) homeostasis and hematopoietic suppo...
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
Histiocytic neoplasms are a rare group of diseases with significant morbidity due to histiocytic infi...
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset au...
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
The use of measurable residual disease (MRD) as a biomarker for prognostication, risk stratification, and therapeutic deci...
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive malignancy characterized by the aberrant accumulation of imma...
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts
Genome-first determination of the prevalence and penetrance of eight germline myeloid malignancy predisposition genes: a study of two population-based cohorts
It is estimated that 10% of individuals with a myeloid malignancy carry a germline susceptibility. Using the genome-first ...
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia
The transcription factor MYB is frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL), a hematological mal...
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635–48.A...
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia
The association of graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects after allogeneic stem-cell tra...
Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia
Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia
We performed gene expression profiling of mRNA/cDNA isolated from N = 117 flow sorted CLL. We detected aberran...
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma
Despite advancements in cancer immunotherapy, most lymphomas remain unresponsive to checkpoint inhibitors. P-selectin glyc...
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune therapy. However, challenges remain includ...
Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation
Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation
A total of 757 de novo AML patients were eligible for training cohort, including 401 males and 356 females, with a median ...
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines
Targeted therapeutics for high-risk cancers remain an unmet medical need. Here we report the results of a large-scale scre...
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Gozzetti A, Candi V, Papini G, Bocchia M. Therapeutic advancements in multiple myeloma. Front Oncol. 2014;4:241.Article  ...
MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells
MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells
Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, et al. Stem and progenitor cells in myelodysplastic syndrome...
The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies
The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies
One sixth of human cancers harbor pathogenic germline variants, but few studies have established their functional contribu...
Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities
Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities
Multiple myeloma (MM) remains a difficult-to-treat disease even with the latest therapeutic advances due to the complex, o...
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia
Unraveling vulnerabilities in chronic lymphocytic leukemia (CLL) represents a key approach to understand molecular basis f...
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation
NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation
Nucleophosmin (NPM1) is a nucleolar protein and one of the most frequently mutated genes in acute myeloid leukemia (AML). ...
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance
Burkitt lymphoma (BL) is the most frequent B-cell lymphoma in pediatric patients. While most patients are cured, a fractio...
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma
Horwitz S, O’Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, ph...
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL
Genetic alterations are the cornerstone of risk stratification in B-cell precursor acute lymphoblastic leukemia (BCP-ALL),...
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia
Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. In this study, ...
阅读更多
format_indent_increase